Streetbeat News

CSLLY

CSL Ltd.

https://www.csl.com/

CEO

Paul Perreault

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

Open

86.09

Mkt cap

84B

Volume

5.1K

High

87.30

P/E Ratio

31.73

52-wk high

109.00

Low

86.09

Div yield

0.01

52-wk low

85.70

The article highlights three high-dividend yielding healthcare stocks: Gilead Sciences, GSK, and AbbVie. Analysts have provided ratings and price targets for these stocks, with recent news impacting each. Gilead has a licensing agreement with Dr. Reddy's, GSK received U.S. government funding for bird flu vaccines, and AbbVie is set to announce its Q3 financial results.

Portfolio Pulse from Avi Kapoor

October 07, 2024 | 11:19 am

The U.S. government has allocated $72 million to GSK, Sanofi, and CSL to increase bird flu vaccine production. This funding aims to double the U.S. supply of vaccines, with a target of 10 million doses by early 2025. The companies will produce extra vaccine components and ensure a steady supply of traditional flu vaccines.

Portfolio Pulse from Vandana Singh

October 04, 2024 | 4:31 pm

The U.S. HHS is awarding $72 million in new grants for bird flu vaccine manufacturing to companies including Sanofi, GSK, and CSL. The CDC has confirmed two new human cases of bird flu in California, prompting symptom monitoring on affected dairy farms.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 3:09 pm

Arcturus Therapeutics and CSL Limited's COVID-19 vaccine, ARCT-154, demonstrated superior immunogenicity compared to Pfizer's Comirnaty in a Phase 3 study, even at lower doses. The vaccine showed better antibody responses against various COVID-19 variants, including Omicron, over a year. ARCT-2301, another vaccine from the same platform, also outperformed Comirnaty in inducing neutralizing antibodies.

Portfolio Pulse from Vandana Singh

September 30, 2024 | 3:12 pm

The US Department of Health and Human Services (HHS) announced that eight laboratories have signed royalty-free agreements for H5N1 tests. Moderna has a deal that allows it to pivot to other pandemic threats, though it's too early to determine its vaccine production capacity. The first H5N1 vaccines from CSL Seqirus are expected to be ready by mid-July.

Portfolio Pulse from Benzinga Newsdesk

July 02, 2024 | 2:58 pm

CSL and Arcturus Therapeutics announced that Nature Communications has published pivotal data demonstrating the efficacy and tolerability of their self-amplifying (sa-mRNA) COVID-19 vaccine, ARCT-154. The data shows superior immunogenicity to Omicron BA 4/5 and longer duration of immunity compared to traditional mRNA COVID-19 vaccine boosters.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 12:42 pm

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) has submitted a response for the Marketing Authorization Application (MAA) of neffy to the EMA's CHMP, addressing all previously identified issues. The company anticipates a CHMP opinion in Q2 2024. Additionally, ARS Pharmaceuticals entered into an exclusive licensing agreement with CSL Seqirus, a subsidiary of CSL Limited (ASX:CSL), for the commercialization of neffy in Australia and New Zealand. CSL Seqirus will handle regulatory approval, reimbursement, and commercialization, while ARS Pharmaceuticals will manage manufacturing and supply. The agreement includes an upfront payment to ARS Pharmaceuticals and event-driven milestone payments.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 1:23 pm

The FDA approved Pfizer Inc's gene therapy, Beqvez, for hemophilia B in adults, offering a one-time treatment alternative to regular intravenous infusions. Beqvez demonstrated significant efficacy in the BENEGENE-2 Phase 3A study, leading to a median annualized bleeding rate of zero. Pfizer has launched a warranty program for Beqvez, priced at $3.5 million in the U.S., and is awaiting approval in Europe while already approved in Canada. Pfizer's stock rose 0.88% to $25.48 following the announcement.

Portfolio Pulse from Vandana Singh

April 26, 2024 | 6:30 pm

Travere Therapeutics and CSL Vifor announced that the European Medicines Agency's CHMP has recommended approval of Sparsentan for primary IgA Nephropathy with a urine protein excretion >1.0 g/day. A decision from the European Commission is expected in Q2 2024.

Portfolio Pulse from Benzinga Newsdesk

February 23, 2024 | 12:07 pm

Canaccord Genuity initiated coverage on Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) with a bullish rating, citing the company's proprietary LNP delivery tech and mRNA cargos. They are particularly optimistic about ARCT-032, a cystic fibrosis treatment, which is in Phase 1b trials with interim data expected in H1 2024. A positive outcome could significantly revalue the program. Canaccord set a price target of $81, indicating over 200% upside. Arcturus is also advancing ARCT-810 for OTC deficiency, with Phase 2 trial enrollment underway. Additionally, ARCT-154, a COVID-19 vaccine developed with CSL Ltd (OTC:CSLLY), was approved in Japan. ARCT shares rose 4.07% to $24.29.

Portfolio Pulse from Vandana Singh

December 13, 2023 | 6:34 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.